| Bioactivity | dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses[1]. |
| Sequence | {Lys<C18 acid>}-Lys-Lys-Lys-Gly-Gly-Gly-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Gly-Leu-Gly-Cys (disulfide bridge: Cys13-Cys30) |
| Shortening | {Lys<C18 acid>}-KKKGGGGLSKGCFGLKLDAIGSMSGGLGC (disulfide bridge: Cys13-Cys30) |
| Formula | C141H248N38O36S3 |
| Molar Mass | 3147.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu Z, et al., Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Sci Transl Med. 2024 Aug 21;16(761):eadn0904. |